How Viruses Disarm the Immune System
Credit: McGill University.
How do viruses that cause chronic infections, such as HIV or hepatitis C virus, manage to outsmart their hosts’ immune systems?
The answer to that question has long eluded scientists, but new research from McGill University has uncovered a molecular mechanism that may be a key piece of the puzzle. The discovery could provide new targets for treating a wide range of diseases.
Fighting off infections depends largely on our bodies’ capacity to quickly recognize infected cells and destroy them, a job carried out by a class of immune cells known as CD8+ T cells. These soldiers get some of their orders from chemical mediators known as cytokines that make them more or less responsive to outside threats. In most cases, CD8+ T cells quickly recognize and destroy infected cells to prevent the infection from spreading.
“When it comes to viruses that lead to chronic infection, immune cells receive the wrong set of marching orders, which makes them less responsive,” says Martin Richer, an assistant professor at McGill’s Department of Microbiology & Immunology and senior author of the study, published recently in the journal Immunity.
The research, conducted in Richer’s lab by graduate student Logan Smith, revealed that certain viruses persist by driving the production of a cytokine that leads to modification of glycoproteins on the surface of the CD8+ T cells, making the cells less functional. That maneuver buys time for the pathogen to outpace the immune response and establish a chronic infection. Importantly, this pathway can be targeted to restore some functionality to the T cells and enhance the capacity to control infection.
The discovery of this regulatory pathway could help identify new therapeutic targets for a variety of diseases. “We might be able to take advantage of the pathways induced by these signals to fight chronic viral infections by making the immune system more responsive,” Richer says. “The findings might also prove useful for diseases like cancer and autoimmunity, where T cells function is poorly regulated.”
This article has been republished from materials provided by McGill University. Note: material may have been edited for length and content. For further information, please contact the cited source.
Interleukin-10 Directly Inhibits CD8+ T Cell Function by Enhancing N-Glycan Branching to Decrease Antigen Sensitivity. Logan K. Smith, Giselle M. Boukhaled, Stephanie A. Condotta, Sabrina Mazouz, Jenna J. Guthmiller, Rahul Vijay, Noah S. Butler, Julie Bruneau, Naglaa H. Shoukry, Connie M. Krawczyk, Martin J. Richer. Immunity In Press DOI: https://doi.org/10.1016/j.immuni.2018.01.006.
Calidi Biotherapeutics, Inc. Announces its Corporate Vision in Groundbreaking Cancer Drug DevelopmentNews
Calidi Biotherapeutics, Inc., formerly StemImmune, Inc., a clinical‐stage biotherapeutics company at the forefront of oncolytic virus-based immunotherapies for cancer, announced a focused effort to advance its oncolytic virus drug development.READ MORE
Bicycle Therapeutics Expands Strategic Partnership with AstraZenecaNews
New programs added in respiratory and cardio-metabolic diseases.READ MORE
Prime Oyster Area Has Worryingly High Concentrations of MicroplasticsNews
BC’s premier shellfish farming region is heavily contaminated with microplastics, according to a new study. The findings show action is required to reduce the environmental impact and entry to the food chain.READ MORE
Comments | 0 ADD COMMENT
Like what you just read? You can find similar content on the communities below.Analysis & Separations Biopharma Cell Science Drug Discovery Proteomics & Metabolomics Immunology & Microbiology
To personalize the content you see on Technology Networks homepage, Log In or Subscribe for FreeLOGIN SUBSCRIBE FOR FREE